Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | Novel insights from BTOG 2023

Tom Newsom-Davis • 3 May 2023
BTOG 2023
General Antibodies Checkpoint Inhibitors Pembrolizumab

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital, London, UK, shares his thoughts on some of the interesting presentations held at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 including one by NHS England’s Steve Williamson on the challenges faced by NHS England in implementing new drug regimens in the UK. This interview took place at BTOG 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tom Newsom-Davis

1:53
The role of NICE in the UK for lung cancer
Tom Newsom-Davis • 27 Apr 2023
1:57
BTOG 2021 highlights: immunotherapy for mesothelioma and cardiac toxicity updates
Tom Newsom-Davis • 23 Apr 2021
2:39
COVID-19 and the future of lung cancer treatment in the UK
Tom Newsom-Davis • 23 Apr 2021
1:40
Dr Newsom-Davis: BTOG 2020 highlights & priorities
Tom Newsom-Davis • 31 Jan 2020

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals